Effects of Supplemental Vitamin D3, Omega-3 Fatty Acids on Physical Performance Measures in the VITamin D and OmegA-3 TriaL
- PMID: 38488491
- PMCID: PMC11651677
- DOI: 10.1210/clinem/dgae150
Effects of Supplemental Vitamin D3, Omega-3 Fatty Acids on Physical Performance Measures in the VITamin D and OmegA-3 TriaL
Abstract
Context: Declining muscle strength and performance in older adults are associated with falls, fractures, and premature death.
Objective: This work aimed to determine whether supplementation with vitamin D3 or omega-3 fatty acids vs placebo for 2 years improves physical performance measures.
Methods: VITamin D and OmegA-3 TriaL (VITAL) was a double-blinded, placebo-controlled randomized trial of supplemental vitamin D3 and/or omega-3 fatty acids vs placebo in the prevention of cancer and cardiovascular disease in 25 871 US adults. This ancillary study was completed in a New England subcohort that had in-person evaluations at baseline and 2-year follow-up. This study was conducted with 1054 participants (age: men ≥50 and women ≥55 years) at the Center for Clinical Investigations in Boston. Interventions included a 2 × 2 factorial design of supplemental vitamin D3 (cholecalciferol, 2000 IU/day) and/or marine omega-3 fatty acids (1 g/day). Main outcome measures included 2-year changes in physical performance measures of grip strength, walking speed, standing balance, repeated chair stands, and Timed-up and Go (TUG).
Results: At 2 years, all randomized groups showed worsening walking speeds and TUG. There were no differences in changes in grip strength, walking speeds, Short Physical Performance Battery (composite of walking speed, balance, and chair stands), and TUG between the vitamin D3-treated and the placebo-treated groups and between the omega-3-treated and the placebo-treated groups. Effects overall did not vary by sex, age, body mass index, or baseline measures of total or free 25-hydroxyvitamin D (25[OH]D) or plasma omega-3 index; TUG slightly worsened with vitamin D supplementation, compared to placebo, in participants with baseline total 25(OH)D levels above the median (P = .01; P for interaction = .04).
Conclusion: Neither supplemental vitamin D3 nor marine omega-3 fatty acids for 2 years improved physical performance in this generally healthy adult population.
Keywords: omega-3 fatty acids; physical performance; vitamin D.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Comment in
-
Is it Time for a Genuine Placebo-controlled Trial on Effects of Vitamin D?J Clin Endocrinol Metab. 2024 Dec 18;110(1):e186-e187. doi: 10.1210/clinem/dgae345. J Clin Endocrinol Metab. 2024. PMID: 38758974 No abstract available.
References
-
- Onder G, Penninx BWJH, Ferrucci L, Fried LP, Guralnik JM, Pahor M. Measures of physical performance and risk for progressive and catastrophic disability: results from the Women’s health and Aging Study. J Gerontol A Biol Sci Med Sci. 2005;60(1):74‐79. - PubMed
-
- Stel VS, Pluijm SMF, Deeg DJH, Smit JH, Bouter LM, Lips P. Functional limitations and poor physical performance as independent risk factors for self-reported fractures in older persons. Osteoporos Int. 2004;15(9):742‐750. - PubMed
-
- Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004;19(2):265‐269. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 1 UL1 RR025758/AT/NCCIH NIH HHS/United States
- R01 AR059775/NH/NIH HHS/United States
- National Institute of Arthritis Musculoskeletal and Skin Diseases
- R01 AR059775/AR/NIAMS NIH HHS/United States
- U01 CA138962/CA/NCI NIH HHS/United States
- NS/NINDS NIH HHS/United States
- 1UL1TR001102/RR/NCRR NIH HHS/United States
- R01 AR060574/AR/NIAMS NIH HHS/United States
- HL/NHLBI NIH HHS/United States
- R01 AT011729/AT/NCCIH NIH HHS/United States
- National Center for Advancing Translational Science
- R01 CA138962/CA/NCI NIH HHS/United States
- R01 AR070854/AR/NIAMS NIH HHS/United States
- Harvard Clinical and Translational Science Center
- Office of Dietary Supplements
- UL1 TR000170/TR/NCATS NIH HHS/United States
- UL1 TR001102/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
